The Montreal Cognitive Assessment (MoCA) in neuro-oncology: A pilot study of feasibility and utility in telehealth and in-person clinical assessments. Issue 5 (14th May 2022)

• Record Type: Journal Article
• Authors: Jammula, Varna; Rogers, James L; Vera, Elizabeth; Christ, Alexa; Leeper, Heather E; Acquaye, Alvina; Briceno, Nicole; Choi, Anna; Grajkowska, Ewa; Levine, Jason E; Lindsley, Matthew; Reyes, Jennifer; Roche, Kayla N; Timmer, Michael; Boris, Lisa; Burton, Eric; Lollo, Nicole; Panzer, Marissa; Smith-Cohn, Matthew A; Penas-Prado, Marta; Pillai, Valentina; Theeler, Brett J; Wu, Jing; Gilbert, Mark R; Armstrong, Terri S
• Is Part Of: Neuro-oncology practice. Volume 9:Issue 5(2022)
• Page Start: 429
• Page End: 440
• Publication Date: 2022-05-14
• Subjects: CNS tumors -- cognitive dysfunction -- neurocognitive testing -- telehealth; Brain -- Tumors -- Periodicals; Brain -- Cancer -- Periodicals; Nervous system -- Cancer -- Periodicals; 616.99481005
• DOI: 10.1093/nop/npac038
• Languages: English
• ISSNs: 2054-2577

Abstract

Abstract: Background: Cognitive impairments are a common burden for patients with primary CNS tumors. Neuropsychological assessment batteries can be too lengthy, which limits their use as an objective measure of cognition during routine care. The purpose of this study was to evaluate the feasibility and utility of the brief Montreal Cognitive Assessment (MoCA) in routine in-person and telehealth visits (as a result of the global COVID-19 pandemic) with neuro-oncology patients. Methods: Seventy-one adults with primary CNS tumors completed MoCA testing in person (n = 47) and via telehealth (n = 24). Correlation analysis and patient-reported outcomes (PROs), including symptom burden and interference, perceived cognition, general health status, and anxiety and depression, were included in this study. Feasibility was assessed through a provider satisfaction questionnaire. Results: Patients were primarily White (83%), college-educated (71%) males (54%) with high-grade tumors (66%). The average total score on the MoCA administered in person was 25 (range: 6-30), with 34% classified as abnormal, and the average total score via telehealth was 26 (range: 12-30), with 29% classified as abnormal. Providers reported satisfaction in using the MoCA during routine clinical care, both in person and via telehealth. Lower MoCA scores correlated with worse symptom severity, KPS, age, education, and previous treatment. Conclusions: The MoCA was feasible in clinical and telehealth settings, and its relationship to clinical characteristics and PROs highlights the need for both objective and patient-reported measures of cognition to understand the overall cognitive profile of a patient with a CNS tumor.